Supplementary Figure S3 from Phase 1/2 Study of the Indoleamine 2,3-Dioxygenase 1 Inhibitor Linrodostat Mesylate Combined with Nivolumab or Nivolumab and Ipilimumab in Advanced Solid Tumors or Hematologic Malignancies
Year: 2025
Type: supplementary-materials
Abstract: Supplementary Figure S3. Outcomes in Patients With Bladder Cancer, Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer Treated With Linrodostat Mesylate Plus Nivolumab During Dose Expansion
Authors: Jason J. Luke, Karen Gelmon, Lillian L. Siu, Victor Moreno, Jayesh Desai, Carlos A. Gomez-Roca, Matteo S. Carlino, Russell K. Pachynski, Rasha Cosman, Quincy Siu-Chung Chu, Silvia Damian, Giuseppe Curigliano, Rachel Tam, Xianling Wang, Chandrika Jeyamohan, Lily Wang, Li Zhu, Julia Santucci-Pereira, Danielle M. Greenawalt, Josep Tabernero
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4411003545